Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linagliptin/metformin - Boehringer Ingelheim/Eli Lilly and Company

Drug Profile

Linagliptin/metformin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI 10773/linagliptin FDC (high dose) - Boehringer Ingelheim; Jentadueto; Jentadueto XR; JentaDuo; linagliptin and metformin hydrochloride extended-release; Linagliptin/metformin FDC; Metformin/linagliptin; Trajenta Duo

Latest Information Update: 14 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly and Company
  • Class Alkynes; Antihyperglycaemics; Biguanides; Insulin sensitisers; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 14 Feb 2019 Chemical structure information added
  • 15 Aug 2018 Depomed is now called Assertio Therapeutics
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top